Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials
Jacob P. Kelly(Duke University), Carolyn S.P. Lam(University of Glasgow), Bertram Pitt(Bayer (Germany)), Mona Fiuzat(Duke University), Adriaan A Voors(University Medical Center Groningen), Robert J. Mentz(Duke University), Javed Butler(Saint Luke's Health System), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Lothar Roessig(Bayer (Germany)), Christopher M. O’Connor(Inova Health System), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy)
Cited by 139
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k